NCT01693549已完成2 期
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Hellenic Cooperative Oncology Group17 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 84
- 试验地点
- 17
- 主要终点
- Objective response rate (ORR).
研究概览
简要总结
The purpose of this study is to determine whether cabazitaxel is effective in the treatment of metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Female patients aged 18 to 75 years
- •Patients must have received 1st-line chemotherapy for locally recurrent / metastatic disease
- •Prior taxane-containing treatment (paclitaxel, docetaxel or nab-paclitaxel), either for advanced disease or as neoadjuvant/adjuvant chemotherapy. In case of early relapse (relapse during neoadjuvant/adjuvant chemotherapy or disease-free interval less than 6 months), neoadjuvant/adjuvant chemotherapy will be considered as 1st-line treatment
- •Diagnosis of HER-2 negative (HER-2 <2+ by immunohistochemistry and/or FISH or CISH negative) metastatic breast adenocarcinoma confirmed by the pathology department of the enrolling institution
- •Eastern Cooperative Oncology Group performance status (PS) of 0-1
- •Life expectancy of at least 12 weeks
- •Measurable disease by the Response Criteria in Solid Tumors 1.1 (RECIST 1.1) method (at least one measurable lesion)
- •Laboratory values within the specified ranges within 1 week of study enrolment:
- •Hemoglobin ≥ 9.0 g/dL
- •Absolute neutrophil count of ≥ 1.5 x 10^9/L
- •Thrombocyte count of ≥ 100 x 10^9/L
- •Serum creatinine ≤ 1.5 upper limit of normal (ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded
- •SGOT (AST), SGPT (ALT) ≤ 2.5 x ULN and alkaline phosphatase ≤ 2.5 x ULN, total bilirubin ≤ ULN (the same limits also refer to patients with liver metastases)
- •Previous treatment for loco-regional disease is allowed, including surgical procedures or palliative radiotherapy (such treatments must have been completed at least 4 weeks before enrolment)
- •Compliance of the patient regarding scheduled visits, treatment plan, laboratory tests and other procedures of the study.
- •The enrolment of patients with controlled brain metastases is allowed (metastases that have been treated with radiotherapy and remained stable for at least 4 weeks following the completion of radiation treatment)
排除标准
- •Patients that have received more than one lines of chemotherapy for locally recurrent/metastatic disease
- •Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a wash-out period of two weeks is necessary for patients who are already on these treatments)
- •Patients with CTC grade 2 or greater neuropathy at baseline
- •Diagnosis of spinal cord compression or carcinomatous meningitis
- •Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
- •Patients with clinically significant cardiac disease (e.g. congestive heart failure, unstable angina, myocardial infarction) within 6 months from study entry
- •Any other significant acute or chronic medical or psychiatric condition or abnormal laboratory finding which, according to the investigator's opinion, could result in excessive danger, regarding the participation of the patient in the study.
- •Psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocol
- •Any concurrent active malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix
- •Concurrent administration of other investigational treatments and/or anti-neoplastic agents
- •Pregnancy or lactation. Patients should be surgically sterile or post-menopausal or they must agree to use adequate contraceptive methods during study period. For all patients of childbearing potential a serum or urine pregnancy test is needed. The definition of effective contraceptive methods will be based on the investigator's opinion.
- •History of severe hypersensitivity reaction (≥grade 3) to docetaxel or polysorbate 80 containing drugs
研究组 & 干预措施
Cabazitaxel
Experimental
Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
干预措施: Cabazitaxel (Drug)
结局指标
主要结局
Objective response rate (ORR).
时间窗: At an average of 24 months for each patient
次要结局
- Evaluation of overall survival (OS)(Defined as the time in months from study entry until the time of death, assessed up to 30 months.)
- Value of prognostic and/or predictive biomarkers measured in tissue and blood samples(Tumor blocks and blood DNA will be collected at study entry and plasma at study entry, on week 3 and week 6 of treatment.)
- Evaluation of progression-free survival (PFS)(From study entry until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression, assessed up to 30 months.)
- Assessment of safety and tolerability.(Evaluation of Adverse Events will be performed every 21 days (per cycle) during treatment assessed up to 30 months.)
- Duration of response.(From the time measurement criteria are first met for partial or complete response until the first date of documented progressive disease or death from any cause without prior documentation of progression assessed up to 30 months.)
研究者
研究点 (17)
Loading locations...
相似试验
终止
2 期
Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard TreatmentColorectal CancerNCT02204332Hospital Clinico Universitario de Santiago38
进行中（未招募）
1 期
Study of cabazitaxel in patients with metastatic breast cancer previously treated with taxanesEUCTR2011-003625-97-GRHellenic Cooperative Oncology Group
终止
2 期
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesMetastatic Breast Cancer With Intracranial MetastasesNCT01934894SCRI Development Innovations, LLC11
终止
2 期
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo RegimenEsophagealGastrooesophageal CancerGastric CancerNCT01365130howard safran15
已完成
1 期
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior ChemotherapyGastric CancerNCT01497964Sanofi16